Indication
In combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:
- durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)
- durvalumab in combination with olaparib in endometrial cancer that ismismatch repair proficient (pMMR).
Medicine details
- Medicine name:
- durvalumab (Imfinzi)
- SMC ID:
- SMC2797
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC